Orchid Chemicals & Pharmaceuticals is currently trading at Rs 174.25, down by 7.75 points or 4.26% from its previous closing of Rs 182.00 on the BSE.
The scrip opened at Rs 184.00 and has touched a high and low of Rs 184.30 and Rs 170.25 respectively. So far 389279 shares were traded on the counter.
The BSE group 'B' stock of face value Rs 10 has touched a 52 week high of Rs 344.40 on 26-Oct-2010 and a 52 week low of Rs 165.00 on 09-Aug-2011.
Last one week high and low of the scrip stood at Rs 205.00 and Rs 170.25respectively. The current market cap of the company is Rs 1282.05 crore.
The promoters holding in the company stood at 30.53% while Institutions and Non-Institutions held 20.15% and 44.75% respectively.
A fire broke out in portion of the New Drug Discovery Laboratories located in the Chennai-based Orchid Research Laboratories, research subsidiary of Orchid Chemicals & Pharmaceuticals. The fire was brought under control by the Tamil Nadu Fire Services squad assisted by the Orchid safety team.
There was damage to office and laboratory equipment, furniture and building interiors. However, there were no injuries to anyone.
Orchid is a pharmaceutical company engaged in development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. The company was incorporated in the year 1992 as a 100% export-oriented unit (EOU).
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1887.95 |
| Dr. Reddys Labs. | 1348.70 |
| Cipla | 1431.65 |
| Zydus Lifesciences | 1149.00 |
| Lupin | 2457.45 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: